{
    "clinical_study": {
        "@rank": "33643", 
        "arm_group": {
            "arm_group_label": "MEDI4736", 
            "arm_group_type": "Experimental", 
            "description": "Evaluate MEDI4736 in MDS"
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity\n      of MEDI4736 in subjects with myelodysplastic syndrome."
        }, 
        "brief_title": "Phase 1 Study to Evaluate MEDI4736", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets\n      programmed cell death-1 ligand 1 [PD-L1]) to evaluate the safety, tolerability, PK, IM, and\n      antitumor activity of MEDI4736 in adult patients with myelodysplastic syndrome."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Adult male or female subjects with pathologically confirmed MDS who failed to respond,\n        relapsed after an initial response, or were unable to tolerate hypomethylating agents,\n        ECOG performance status of 0 - 2, and adequate organ and marrow function.\n\n        Exclusion Criteria:\n\n        Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer\n        treatment, prior MAb against CTLA-4, PD-1, or PD-L1, alllogenic or haploidentical\n        transplant, current immunosuppressive medication or autoimmune or inflammatory disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117219", 
            "org_study_id": "D4190C00007"
        }, 
        "intervention": {
            "arm_group_label": "MEDI4736", 
            "description": "MEDI4736 will be administered by IV infusion", 
            "intervention_name": "MEDI4736", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Myelodysplastic syndrome", 
            "MDS"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents", 
        "overall_contact": {
            "email": "ClinicalTrialEnquiries@Medimmune.com", 
            "last_name": "Heidi Kacprowicz", 
            "phone": "301-398-0000"
        }, 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "Joyson Karakunnel, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DLT assessment will be done by reviewing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, physical examinations, and electrocardiogram (ECG) results.", 
            "measure": "Subject's safety where no more than one out of six subjects experience DLTs at a given dose.", 
            "safety_issue": "Yes", 
            "time_frame": "455 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117219"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "As defined by IWG 2006 MDS response criteria", 
                "measure": "Clinical outcome in terms of response: duration of response", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "As defined by IWG 2006 MDS response criteria and incidence of transfusions.", 
                "measure": "Clinical outcome in terms of response: transfusion requirements", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "As defined by IWG 2006 MDS response criteria", 
                "measure": "Clinical outcome in terms of response: progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "As defined by IWG 2006 MDS response criteria and collection of survival data", 
                "measure": "Clinical outcome in terms of response: survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Peak concentration of MEDI4736 in serum", 
                "measure": "Pharmacokinetics: MEDI4736 concentrations in serum: peak concentration", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Analysis of area under the concentration-time curve", 
                "measure": "Pharmacokinetics: MEDI4736 concentrations in serum: area under the concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Rate of MEDI4736 clearance", 
                "measure": "Pharmacokinetics: MEDI4736 concentration in serum: clearance", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "MEDI4736 concentration terminal half-life", 
                "measure": "Pharmacokinetics: MEDI4736 concentration in serum: terminal half-life", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Determine by number of subjects who develop ADA (anti-drug antibody).", 
                "measure": "Immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Rate of AML transformation.", 
                "measure": "AML (Acute Myeloid Leukemia) transformation", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Analysis of reporting of disease- and treatment-related symptoms", 
                "measure": "Health-related quality of life (QOL): disease- and treatment-related symptoms", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Analysis of incidence of pain reporting", 
                "measure": "Health-related quality of life (QOL): pain", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Analysis of reporting of health status.", 
                "measure": "Health-related quality of life (QOL): health status", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}